JP6085866B2 - セリン／トレオニンキナーゼインヒビター - Google Patents

セリン／トレオニンキナーゼインヒビター Download PDF

Info

Publication number
JP6085866B2
JP6085866B2 JP2013556817A JP2013556817A JP6085866B2 JP 6085866 B2 JP6085866 B2 JP 6085866B2 JP 2013556817 A JP2013556817 A JP 2013556817A JP 2013556817 A JP2013556817 A JP 2013556817A JP 6085866 B2 JP6085866 B2 JP 6085866B2
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
optionally substituted
cancer
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013556817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506930A (ja
JP2014506930A5 (enExample
Inventor
ジェームス エフ． ブレーク，
ジェームス エフ． ブレーク，
フイフェン チェン，
フイフェン チェン，
マーク ジョセフ シカレリ，
マーク ジョセフ シカレリ，
ジェイソン デミーズ，
ジェイソン デミーズ，
ルスタム ガリー，
ルスタム ガリー，
ジョン ジェイ． ゴーディノ，
ジョン ジェイ． ゴーディノ，
ロバート ジェイ． カウス，
ロバート ジェイ． カウス，
ガブリエル アール． コラカウスキー，
ガブリエル アール． コラカウスキー，
アリソン エル． マーロウ，
アリソン エル． マーロウ，
ピーター ジェイ． モーア，
ピーター ジェイ． モーア，
リー レン，
リー レン，
ジェイコブ シュワルツ，
ジェイコブ シュワルツ，
クリストファー エス． シーデム，
クリストファー エス． シーデム，
アレン エー． トーマス，
アレン エー． トーマス，
エリー ウォーレース，
エリー ウォーレース，
スティーブン マーク ウェングロウスキー，
スティーブン マーク ウェングロウスキー，
スティーブン ボイド，
スティーブン ボイド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2014506930A publication Critical patent/JP2014506930A/ja
Publication of JP2014506930A5 publication Critical patent/JP2014506930A5/ja
Application granted granted Critical
Publication of JP6085866B2 publication Critical patent/JP6085866B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013556817A 2011-02-28 2012-02-28 セリン／トレオニンキナーゼインヒビター Active JP6085866B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161447587P 2011-02-28 2011-02-28
US61/447,587 2011-02-28
PCT/US2012/027009 WO2012118850A1 (en) 2011-02-28 2012-02-28 Serine/threonine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2014506930A JP2014506930A (ja) 2014-03-20
JP2014506930A5 JP2014506930A5 (enExample) 2015-04-02
JP6085866B2 true JP6085866B2 (ja) 2017-03-01

Family

ID=45852719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013556817A Active JP6085866B2 (ja) 2011-02-28 2012-02-28 セリン／トレオニンキナーゼインヒビター

Country Status (11)

Country Link
US (1) US9133187B2 (enExample)
EP (1) EP2681215B1 (enExample)
JP (1) JP6085866B2 (enExample)
KR (1) KR101961500B1 (enExample)
CN (1) CN103635472B (enExample)
BR (1) BR112013021896A2 (enExample)
CA (1) CA2828478C (enExample)
ES (1) ES2543050T3 (enExample)
MX (1) MX339873B (enExample)
RU (1) RU2013143839A (enExample)
WO (1) WO2012118850A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543050T3 (es) 2011-02-28 2015-08-14 Array Biopharma, Inc. Inhibidores de serina/treonina quinasa
PE20140868A1 (es) 2011-06-24 2014-07-18 Amgen Inc Antagonistas trpm8 y su uso en tratamientos
CA2839703A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
EP2739618B1 (en) * 2011-08-04 2015-09-16 Array Biopharma, Inc. Quinazoline compounds as serine/threonine kinase inhibitors
BR112014015482A8 (pt) * 2011-12-27 2017-07-04 Bio Pharm Solutions Co Ltd compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
AR090220A1 (es) 2012-03-01 2014-10-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
MX369989B (es) 2012-08-27 2019-11-27 Array Biopharma Inc Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas.
CN104640865B (zh) * 2012-09-19 2018-05-11 诺华股份有限公司 作为激酶抑制剂的二氢吡咯烷子基-嘧啶
JP2015533151A (ja) 2012-10-16 2015-11-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト セリン／スレオニンキナーゼ阻害剤
EP3026051A4 (en) * 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US9867833B2 (en) 2013-12-06 2018-01-16 Genentech, Inc. Serine/threonine kinase inhibitors
CA2934679C (en) 2013-12-30 2023-02-28 Genentech, Inc. Serine/threonine kinase inhibitors
WO2015103137A1 (en) 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
EP3458445B1 (en) * 2016-05-18 2021-02-17 Mirati Therapeutics, Inc. Kras g12c inhibitors
US11859252B2 (en) 2017-09-08 2024-01-02 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US11053217B2 (en) 2017-09-29 2021-07-06 Mitsubishi Tanabe Pharma Corporation Optically active pyrrolidine compound and method for producing same
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
JP2022527744A (ja) 2019-03-28 2022-06-06 ジエンス ヘンルイ メデイシンカンパニー リミテッド チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用
JP2022528083A (ja) 2019-03-29 2022-06-08 ジエンス ヘンルイ メデイシンカンパニー リミテッド ピロロ複素環式誘導体、この誘導体のための調製方法及び医学におけるこの誘導体の用途
TW202110837A (zh) * 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
JP2022534224A (ja) 2019-05-24 2022-07-28 江蘇恒瑞医薬股▲ふん▼有限公司 置換縮合二環式誘導体、その調製方法、および医薬におけるその適用
CN111170929A (zh) * 2019-12-12 2020-05-19 北京达因高科儿童药物研究院有限公司 一种由末端烯烃制备β-氨基醇的方法
KR20230074762A (ko) * 2020-09-25 2023-05-31 얀센 파마슈티카 엔.브이. 사이클린-의존성 키나제 7(cdk7) 비-공유 저해제
JP2023543080A (ja) 2020-09-29 2023-10-12 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ピロロ複素環系誘導体の結晶及びその製造方法
CN115040522B (zh) * 2022-06-30 2024-02-06 牡丹江医学院 一种用于治疗肺癌的药物及其制备方法
JP2025536384A (ja) * 2022-10-25 2025-11-05 上海拓界生物医薬科技有限公司 ピペリジノピリミジン系誘導体、その調製方法及びその医薬的使用
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3
WO2025087267A1 (zh) * 2023-10-23 2025-05-01 上海拓界生物医药科技有限公司 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
WO2025223512A1 (zh) * 2024-04-24 2025-10-30 江苏恒瑞医药股份有限公司 一种二氢吡啶并嘧啶衍生物的可药用盐、结晶形式及用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
PT672042E (pt) 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CZ9902016A3 (cs) 1996-12-05 1999-11-17 Amgen Inc. Substituované pyrimidinonové a pyridonové sloučeniny a způsoby jejich použití
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
RU2277911C2 (ru) 2000-02-25 2006-06-20 Ф.Хоффманн-Ля Рош Аг Модуляторы аденозиновых рецепторов
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
AU2003234628B2 (en) 2002-05-21 2007-08-23 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2004007468A1 (en) * 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
JP2007532669A (ja) 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリミジン
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006021458A2 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
CA2606288A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
US20100022531A1 (en) * 2005-09-01 2010-01-28 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
KR20080103996A (ko) 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
ES2373587T3 (es) 2006-08-23 2012-02-06 Pfizer Products Inc. Compuestos de pirimidona como inhibidores de gsk-3.
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
EA200900799A1 (ru) 2006-12-22 2009-12-30 Новартис Аг Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями
JP5363350B2 (ja) * 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
WO2009011904A1 (en) * 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
WO2009032861A1 (en) 2007-09-04 2009-03-12 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
BRPI0817135A2 (pt) 2007-11-06 2014-10-07 Du Pont Composto, método de controle de doenças de plantas e composições fungicidas
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
NZ624345A (en) 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
PE20110136A1 (es) 2008-06-27 2011-03-17 Novartis Ag Compuestos organicos
PL2370413T3 (pl) 2008-12-08 2016-01-29 Arena Pharm Inc Modulatory receptora prostacykliny (PGI2) użyteczne w leczeniu zaburzeń z nimi związanych
ES2543050T3 (es) 2011-02-28 2015-08-14 Array Biopharma, Inc. Inhibidores de serina/treonina quinasa
EP2739618B1 (en) 2011-08-04 2015-09-16 Array Biopharma, Inc. Quinazoline compounds as serine/threonine kinase inhibitors
AR090220A1 (es) 2012-03-01 2014-10-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
MX369989B (es) 2012-08-27 2019-11-27 Array Biopharma Inc Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas.

Also Published As

Publication number Publication date
WO2012118850A1 (en) 2012-09-07
CA2828478A1 (en) 2012-09-07
ES2543050T3 (es) 2015-08-14
JP2014506930A (ja) 2014-03-20
BR112013021896A2 (pt) 2016-11-08
US9133187B2 (en) 2015-09-15
MX339873B (es) 2016-06-15
RU2013143839A (ru) 2015-04-10
EP2681215B1 (en) 2015-04-22
MX2013009877A (es) 2014-02-11
US20130338140A1 (en) 2013-12-19
KR20140014190A (ko) 2014-02-05
CN103635472A (zh) 2014-03-12
CA2828478C (en) 2019-12-31
KR101961500B1 (ko) 2019-03-22
EP2681215A1 (en) 2014-01-08
CN103635472B (zh) 2018-01-12

Similar Documents

Publication Publication Date Title
JP6085866B2 (ja) セリン／トレオニンキナーゼインヒビター
JP7374960B2 (ja) 縮合環化合物
US8962642B2 (en) 5-cyano-4- (pyrrolo [2,3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
CN105732636B (zh) 杂芳化合物及其在药物中的应用
US20240383915A1 (en) Oxazepine compounds and uses thereof in the treatment of cancer
CN103102344B (zh) 氨基喹唑啉类衍生物及其盐和使用方法
KR101979042B1 (ko) 세린/트레오닌 키나제 억제제로서의 퀴나졸린 화합물
JP6378182B2 (ja) 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
CN115135642A (zh) Egfr突变形式的抑制剂
KR20250013185A (ko) 아자-테트라시클릭 옥사제핀 화합물 및 이의 용도
US8288381B2 (en) N-9 substituted purine compounds, compositions and methods of use
AU2014259477A1 (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors for the treatment of cancer
EP2499143A1 (en) N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
CN113912628A (zh) 三嗪类化合物及其组合物和用途
TW201516045A (zh) 絲胺酸／蘇胺酸激酶抑制劑
US20150031674A1 (en) Serine/threonine kinase inhibitors
HK1191010A (en) Serine/threonine kinase inhibitors
US20250235456A1 (en) Methods of use for aza-quinazoline compounds
HK1191010B (en) Serine/threonine kinase inhibitors
HK1172328B (en) N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170113

R150 Certificate of patent or registration of utility model

Ref document number: 6085866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250